Personalis Pre-Paid Expenses 2018-2024 | PSNL

Personalis pre-paid expenses from 2018 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Personalis Annual Pre-Paid Expenses
(Millions of US $)
2023 $4
2022 $7
2021 $7
2020 $5
2019 $3
2018 $2
2017 $
Personalis Quarterly Pre-Paid Expenses
(Millions of US $)
2024-09-30 $5
2024-06-30 $4
2024-03-31 $5
2023-12-31 $4
2023-09-30 $6
2023-06-30 $5
2023-03-31 $8
2022-12-31 $7
2022-09-30 $8
2022-06-30 $6
2022-03-31 $6
2021-12-31 $7
2021-09-30 $8
2021-06-30 $9
2021-03-31 $6
2020-12-31 $5
2020-09-30 $5
2020-06-30 $3
2020-03-31 $3
2019-12-31 $3
2019-09-30 $4
2019-06-30 $2
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.396B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $24.935B 8.18
Dr Reddy's Laboratories (RDY) India $12.596B 24.10
BridgeBio Pharma (BBIO) United States $6.773B 0.00
Bausch Health Cos (BHC) Canada $2.792B 2.06
Supernus Pharmaceuticals (SUPN) United States $2.108B 28.70
Amphastar Pharmaceuticals (AMPH) United States $1.738B 10.44
Taysha Gene Therapies (TSHA) United States $0.314B 21.86
Assembly Biosciences (ASMB) United States $0.095B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00